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Background: Three decades of research findings have documented the health effects of handling hazardous drugs.
Oncology nurses are vulnerable due to frequent administration of antineoplastics, low adherence to equipment use,
reported barriers to use, and perceived low risk of health effects. No interventions have been tested in a controlled,
multi-site trial to increase nurses’ use of protective equipment when handling hazardous drugs. The Drug Exposure
Feedback and Education for Nurses’ Safety (DEFENS) study will compare the efficacy of education (control) versus
an audit and feedback intervention (treatment) on nurses’ self-reported use of personal protective equipment when
handling hazardous drugs. The treatment intervention will include tailored messages based on nurses’ reported
barriers to protective equipment use.
Methods/Design: The DEFENS Study is a cluster randomized controlled trial. We are enrolling cancer centers and
will recruit nurse participants in April 2015. Eligible cancer centers employ at least 20 eligible registered nurses in
the chemotherapy infusion setting and have on-site phlebotomy resources. Eligible participants are nurses who
work at least 0.40 full-time equivalent hours in the chemotherapy infusion setting and have not received an
antineoplastic drug for a health problem in the past year. An encrypted, user-authenticated website will administer
surveys and deliver control and treatment interventions. The primary endpoint is the change in score on nurses’
reports of the Revised Hazardous Drug Handling Questionnaire between baseline and approximately 18 months
later. A baseline survey is completed after informed consent and is repeated 18 months later. Nurses in all sites
who experience a drug spill will also report incidents as they occur; these reports inform the treatment intervention.
Plasma will be obtained at baseline, approximately 18 months later (the primary endpoint), and with drug spill
occurrences to measure hazardous drugs levels and to inform the treatment intervention. Potential mediators
include knowledge of hazardous drug handling and perceived risk of drug exposure. We will examine whether
personal factors and organizational factors moderate the intervention effects.
Trial registration: Clinicaltrials.gov NCT02283164, registered 31 October 2014.
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For over three decades, scientists have documented the per-
nicious effects of handling hazardous drugs such as antineo-
plastics [1-5]. Reports have identified the following health
effects: acute nausea and vomiting, reproductive difficulties,
cancer, and myelodysplastic syndrome. In 2004, the National
Institute for Occupational Safety and Health (NIOSH) is-
sued an alert that summarized the evidence and recom-
mended that health care settings and employees adopt
practices to minimize the risk of handling potentially haz-
ardous drugs [6]. The Oncology Nursing Society [7] and the
American Society of Health-System Pharmacists [8] pub-
lished guidelines on hazardous drug handling. The NIOSH
2004 recommendations are now included in the 2013
American Society of Clinical Oncology/Oncology Nursing
Society chemotherapy administration safety standards [9].
Published guidelines include the use of personal pro-
tective equipment (PPE), comprised of two pairs of
chemotherapy-tested gloves, single-use disposable gowns,
eye protection during specific activities, and respiratory
protection when vapor exposure is possible. However,
adoption of these guidelines is suboptimal in clinical set-
tings [10]. A statewide survey revealed that 16.9% of
ambulatory oncology nurses reported skin or eye exposure
to chemotherapy in the past year [11]. Increased exposure
is associated with higher nursing workloads and poorer
nurse practice environments. Oncology nurses deliver an
astounding volume of chemotherapy; US estimates suggest
over 18 million doses of chemotherapy are administered
annually in the United States, primarily by nurses [12].
Audit and feedback is an established intervention to
support clinician practice change. Successful audit and
feedback interventions include education and periodic
reminders [13]. Systematic reviews have identified im-
provements in clinician practice after feedback interven-
tions [14]. Using a pre-post design, one Malaysian study
reported increased scores on safe handling knowledge,
beliefs, and observed practices for 96 inpatient nurses
who completed an educational module on hazardous
drug handling [15]. The absence of multi-site, controlled
intervention studies to improve PPE use in ambulatory
oncology nurses is surprising given the large volume of
drugs handled and the potential health risks involved.
In this context, this paper reviews the design of a clus-
ter, randomized controlled trial to evaluate the efficacy
of an audit and feedback intervention to improve nurses’
use of personal protective equipment when handling
hazardous drugs. The overall objective of this research
program is to measure and improve the safety of chemo-
therapy administration in ambulatory oncology settings.
The trial has three specific aims:
1. Evaluate the efficacy of an audit and feedback
intervention to improve recommended use of PPE.2. Determine whether the intervention effects on PPE
use are mediated by knowledge about PPE use and
perceived risk of hazardous drug exposure.
3. Determine whether the intervention effects on PPE
use are moderated by personal (experience,
education, and certification) and organizational
factors (workloads, practice environments, and
safety organizing behaviors).
Study results will inform practicing nurses, cancer
center administrators, and policymakers on optimal ap-
proaches to protect workers who handle potentially haz-
ardous drugs.
Methods/Design
A cluster randomized controlled trial design was chosen
to compare an educational module on hazardous drug
handling with the same educational module plus feedback
from survey and biological data obtained from partici-
pants. Specifically, a clustered design reduces the likeli-
hood for contamination bias between participants and
facilitates measurement of the organizational context that
we hypothesize will moderate the effects of the proposed
intervention. Participants will provide baseline data upon
study enrollment. After evaluation for the primary end-
point is complete, all participants will receive the feedback
materials for the remainder of the 4-year study. These ma-
terials and study questionnaires will be located on a user-
authenticated website maintained by the investigative
team. Table 1 shows the study procedures.
Human subjects considerations
The University of Michigan Institutional Review Board
has approved the study (HUM00086541, date of last ap-
proval: 16 March 2015). All participants will complete
informed consent on the study website. Of the 11 par-
ticipating sites, 4 have reviewed study procedures and
determined their staff to be 'not engaged' in the conduct
of the research. Another three sites have ceded authority
to the University of Michigan and the remaining four
sites have pursued full protocol review. Recruitment will
not begin at each site until local approvals have been ob-
tained, as appropriate. A complete listing of human sub-
jects approval is available (see Additional file 1).
Conceptual framework
The study’s conceptual framework integrates theoretical,
empirical, and pilot work that spans occupational health,
health promotion, and organizational studies (Figure 1)
[16-19]. The primary outcome of interest is PPE use
using a valid and reliable measure described below [10].
The interventions are a 1-hour web-based educational
module on hazardous drug safe handling with quarterly
reminders about the educational content (control) or the
Table 1 Drug Exposure Feedback and Education for Nurses' Safety (DEFENS) Study procedures
Enrollment Allocation Post-allocation Close-out
TIMEPOINT (Month) 1-5 6 7 9 12 15 18 21 24 25-30
ENROLLMENT
Eligibility screen X
Informed consent X
Site Coordinator Training X
Cluster Allocation X
INTERVENTIONS
Control: Web-based educational module X
Intervention: Audit and Feedback X X (both arms) X X
Quarterly Reminders X X X X X X X
ASSESSMENTS
Baseline Survey Demographics, PPE use, Plasma levels,
PPE Knowledge, PPE Barriers, Moderators
X
Primary Endpoint PPE use, Plasma levels X
Spill Assessments PPE use, Plasma levels X X X X X X X X
PPE: Personal protective equipment.
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plus quarterly feedback on hazardous drug spills and
drug levels measured in the study population (treat-
ment). Aim 1 will compare the control and treatment
groups on PPE use. Next, we hypothesize the interven-
tions will result in a) increased knowledge [20] about
PPE use and b) increased perceived risk [21] of hazard-
ous drug exposure. We hypothesize the treatment inter-
vention will result in higher knowledge and perceived
risk than the control intervention. In Aim 2, knowledge
and perceived risk are considered mediators of theFigure 1 Conceptual framework. NIOSH: National Institute for Occupationaintervention effect because they are likely influenced by
the intervention received and in turn will likely influence
PPE use. Finally, preliminary work suggests a relation-
ship between the personal factor of years of experience
and PPE use. We will also explore additional personal
factors, including nursing education and certification.
Two organizational factors (nursing workloads and
practice environments) are correlated to PPE use and
hazardous drug exposure [11]. We will also explore a
third factor of safety organizing behaviors [22]. In Aim
3, personal and organizational factors are consideredl Safety and Health. ONS: Oncology Nursing Society.
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or weaken the observed effect of the interventions on
PPE use.
Setting and sample
Settings
Site inclusion criteria are ambulatory oncology infusion
settings with at least 20 employees who meet the eligibil-
ity criteria listed below. In addition, the chief nursing ex-
ecutive for cancer services in each facility provided
endorsement of the study. Exclusion criteria are infusion
areas that are not within easy access to the on-site study
coordinator’s office or lack on-site phlebotomy services.
Sample
Primary inclusion criteria include registered nurses
employed 16 hours or more per week in the ambula-
tory infusion area. To eliminate the chance of contami-
nated results in accordance with a previous protocol
[23], exclusion criteria include treatment with an anti-
neoplastic agent in the past year. Women who are
pregnant will be allowed to participate but for safety
reasons, will not have blood drawn.
Recruitment and retention
The principal investigator will visit each site and offer
a live presentation that reviews study procedures. The
presentation will be recorded so off-shift workers may
view the material at their convenience. Our recruit-
ment strategy incorporates procedures supported by
Dillman’s Tailored Design Method [24]. Chief nursing
executives for cancer services have endorsed the study
and will co-sign all recruitment materials. Site leaders
will provide a list of all nurses who meet employment
criteria, and personalized Emails will be sent to each
nurse by the site leader and co-signed by the principal
investigator. An upfront $10 cash gift will be provided
during the enrollment period. Each site will also have
at least one study coordinator who is fully versed on
the scientific protocol and who can direct study ques-
tions to the coordinating center.Table 2 Control and treatment interventions description
Control Tre
Format Web-based We
Duration Forty-five minutes of audio/video content Sixt
Content Review of 2004 NIOSH alert and recommendations
for practice
Con
stra
Tailored Messaging No Yes
Fidelity Assessment Completion of post test Com
Reminders Email reminders every 3 months of content Em
NIOSH: National Institute for Occupational Safety and Health; PPE: personal protectiTo promote retention, we plan quarterly electronic up-
dates to all sites through personalized Email messages from
the coordinating center. The study website was developed
by a professional vendor with expertise in user-centered
design [25]. These efforts ensure study participants can
navigate the website easily. At our post-intervention data
collection point, participants will receive electronic and in-
person cues to complete the survey, have blood draws per-
formed, and receive a second $10 cash gift.
Randomization
Randomization will occur after participants have enrolled
and completed the baseline survey. Randomization will
occur at the site, rather than the participant level, to re-
duce the likelihood of contamination across study arms
within one cancer center. We recognize the sites vary by
size. To address this, sites will be ordered by number of
participants in decreasing order. The .ralloc command in
Stata 12 (StataCorp, College Station, TX, USA) will per-
form random allocation in blocks of two so that one of the
first two sites is in each condition. This will help ensure
fairly equal sample size in the two groups.
Education versus audit and feedback
Both the control and treatment interventions are deliv-
ered to individual nurse participants. Table 2 compares
the control and treatment interventions.
Control: hazardous drug safe handling web-based educational
module with quarterly reminders
Participants will view a 1-hour web-based educational
module on safe handling procedures. Our study consultant
will present a 1-hour informational webinar on principles
of hazardous drug handling, consistent with Oncology
Nursing Society chemotherapy guidelines [7] and recom-
mendations from NIOSH [26] and the American Society
of Health-System Pharmacists [8]. The module content in-
cludes a summary of the 2004 NIOSH alert regarding the
health effects of hazardous drug handling, a summary of
the recommendations for PPE use, and resources to iden-
tify whether a drug is classified as hazardous. Participants
will complete a post test to measure knowledge of PPEatment
b-based
y minutes of audio/video content
tent from control video + video messages from practicing nurses on
tegies to reduce barriers to PPE use
: tailoring variables are barriers to PPE use measure obtained at baseline
pletion of post test; paradata to track that video messages were viewed
ail messages every 3 months with updates on spill data collected
ve equipment.
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ing nursing education credit will be provided. Every
3 months, short messages that summarize one of the main
points presented during the webinar will be viewable on
the study website.
Treatment: tailored web-based educational module plus
quarterly audit and feedback on spills and drug levels
For the tailored educational module, participants view the
1-hour module on safe handling procedures plus add-
itional short videos tailored on the barriers to PPE use
they reported in the baseline survey [27]. The videos ad-
dress each barrier individually and offer suggestions for
overcoming them. For example, a nurse who scores highly
on the item, 'PPE makes me too hot' on the barriers ques-
tionnaire will view a video from an interviewed oncology
nurse that has successfully addressed that barrier. The
audit and feedback intervention is a video report prepared
every 3 months during the study period. The report sum-
marizes: (1) the number of drug spills reported, (2) the
context of the spill occurrences (when, activities per-
formed, pertinent details, and use of PPE), and (3) drug
levels obtained from participants’ blood samples. The re-
ports are viewable from the study’s secure website. Drug
levels from our baseline assessment and from spills will be
reported using procedures described below.Table 3 Measures table and timing
Concept Measure
Outcome Revised Drug Handling Questionnaire
Mediator: Knowledge Knowledge questionnaire
Mediator: Perceived Risk Three items from Geer’s dermal exposure survey
Personal Factor Experience
Personal Factor Highest education degree completed
Personal Factor Completed certifications
Organizational Factor Workload
Organizational Factor Revised PES-NWI
Organizational Factor Safety Organizing Scale
AOCN: Advanced Oncology Certified Nurse; OCN: Oncology Certified Nurse; ONS: O
Work Index.
Note. Baseline assessment begins in Year 1 of the study; the Primary endpoint is asIntervention fidelity assessment
Fidelity of the control intervention will be assessed
through the quiz required to receive a continuing edu-
cation certificate. Fidelity of both treatments is ex-
pected to be high because delivery of content via a
secure website assures consistent presentation. This
mode of delivery offers greater fidelity than interven-
tions delivered by a person, which can vary over time
and with the person offering the intervention. Prior to
accessing the site, participants will log on using their
unique study identifier, allowing the study team to
track the number of times each user accesses the site.
Access (number of times) and duration (minutes
viewed, longest time between keystrokes) data will be
used in the analyses to assess intervention effects. Be-
cause randomization occurs at the site rather than the
individual, there is minimal opportunity for crossover
contamination bias. The use of unique, secure user
logins and passwords limits access to the intended re-
cipients only.
Measures
Measures were selected for their fit to the conceptual
framework of the study, their performance in previous
studies, and documented validity and reliability (see
Table 3).Description When collected
Five items, 0 to 5 (never to always) use selected
PPE items
Baseline
Primary endpoint
Twelve items, multiple choice, true/false about
2004 NIOSH alert and recommendations
Baseline
After viewing module
Primary endpoint
Three items, score 1 to 4 (strongly disagree -
strongly agree) about health risks from exposure
Baseline
Primary endpoint
Number of years in nursing, oncology nursing,
and in current position
Baseline
Diploma, Associates’ Bachelors, Masters, or
Doctorate
Baseline
ONS Chemotherapy certification, OCN, AOCN Baseline
Number of patients cared for on shift Baseline
With a spill report
Primary endpoint
Six subscales, 23 items, score range 0 to 5
(strongly disagree - strongly agree) about
presence of favorable work features
Baseline
Primary endpoint
Nine items, score range 1 to 7 (not at all - to a
very great extent) team performance of safety
behaviors
Baseline
Primary endpoint
ncology Nursing Society; PES-NWI: Practice Environment Scale of the Nursing
sessed approximately 18 months later.
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The study’s primary endpoint is optimal use of PPE, and
it will be measured at the individual participant level
using the Revised Hazardous Drug Handling Question-
naire originally developed by Martin and Larson [20] as
modified by Polovich and Martin [10]. The items are
mapped to the 2004 NIOSH alert recommendations
[6]. Use of PPE is measured on a 6-point Likert scale
(5 = always, 4 = 76 to 99% of the time, 3 = 51 to 75%, 2 =
26 to 50%, 1 = 1 to 25%, and 0 = never). A mean score is
calculated for each participant across five items: use of
chemotherapy gloves, double gloves, single-use dispos-
able gowns, eye protection, and respirators. Higher
scores reflect more frequent use of PPE elements. In the
original study, test-retest Kappa was calculated at 0.80,
and measure validity was established through direct
observation of nurses who also completed the ques-
tionnaire. In a sample of 165 nurses who completed
the revised scale, the Cronbach alpha was 0.83 [10].
Although the original scale asks separate questions
about drug preparation, drug administration, and drug
disposal activities, this study will focus on PPE use for
drug administration only, an activity shared by all
study participants. This measure will be obtained with
the baseline survey and at the post-intervention
assessment.
Potential mediators
Both knowledge of PPE and perceived risk of hazardous
drug exposure are hypothesized to mediate the poten-
tial effects of the intervention on PPE use. These mea-
sures will be obtained at baseline at the individual
participant level, after the educational module has been
viewed, and at the post-intervention assessment. The
mediator analysis will use the measures obtained after
the intervention has been delivered. Both measures
were validated by expert panel review and discussion
with two focus groups of at-risk workers. In prior work,
both measures achieved a content validity index of 1
from 3 experts [10].
Knowledge of PPE will be measured using a 10-item
chemotherapy exposure questionnaire that assesses
knowledge of the 2004 NIOSH alert. The measure was
developed by a content expert and study consultant.
Each item provides four answer choices with one correct
answer for each question. The scale range is 0 to 10,
with higher scores reflecting increased knowledge. Per-
ceived risk of drug exposure will be measured using a 3-
item subscale from Geer’s Occupational Dermal Survey
[21]. A 4-point Likert scale (1 = strongly disagree, 4 =
strongly agree) will be used to assess nurses’ perceptions
of the risks of chemotherapy exposure and potential
health effects. The score range is 1 to 4. The Cronbach
alpha in a similar study population was 0.70 [10].Potential moderators
Three organizational factors (workloads, practice environ-
ments, and safety organizing) and three personal factors
(experience, education, and certification) are proposed
moderators. These measures will be obtained on the
web-based survey at baseline and the post-intervention as-
sessment. In contrast to our outcomes and potential medi-
ators, the moderators will be obtained from participants
and aggregated to the cluster level.
Workloads will be measured by asking participants:
'How many patients did you assume primary responsibil-
ity for on your last shift?' For spill reporting, the time
referent will be changed to 'the shift the drug spill oc-
curred'. Workload measures correlate significantly with
administratively-derived staffing levels and perceived
staffing adequacy [28]. Workload is also significantly as-
sociated with patient mortality [29], nurse-reported nee-
dlesticks [30], and hazardous drug exposure [11].
Practice environments are workplace features that en-
able nurses to deliver high-quality care [31]. Items from
the Practice Environment Scale of the Nursing Work
Index, revised for ambulatory oncology, are scored on a
5-point Likert scale, where 1 = strongly disagree to 5 =
strongly agree that the characteristic is present in the
practice. The range of setting-level scores on a compos-
ite of the 6 subscales was 2.7 (disagree) to 5.0 (strongly
agree). Previously analyzed for validity and reliability, ac-
ceptable fit was achieved in a structural equation model
with a comparative fit index of 0.95 and a root mean-
square error of approximation of 0.057, and subscale
Cronbach alphas ranged from 0.80 to 0.90 [32]. Our pre-
liminary data show lower scores (that is, poorer practice
environments) for nurses who report hazardous drug
spills. We will use the mean score of the 23-item com-
posite measure for the proposed analyses (range = 1 to 5).
The Safety Organizing Scale [22] reflects behaviors
employees perform in high-reliability organizations that
avert operational failure. Nine items reflect the concept
of a safety culture, and importantly, capture observable
actions of clinicians. Each item is scored on a 7-point
Likert scale (1 = not at all, 7 = to a very great extent) to
reflect the degree to which the nurse and his/her co-
workers engage in the behaviors on their work unit. The
items identify safe performance as a function of five pro-
cesses: preoccupation with failure, reluctance to simplify
interpretations, sensitivity to operations, commitment to
resilience, and deference to expertise. The scale has high
internal reliability and discriminant validity [22].
Congruent with prior studies, the three potential mod-
erators described above will be aggregated to the cluster
level. In this study, a cluster is considered each of the 11
participating cancer centers. For each cluster, the mean
value for these three measures will be calculated from
the individual responses from each nurse in the cluster.
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ticipant with the baseline survey: oncology nursing ex-
perience (years), education (diploma, associate’s degree,
bachelor’s degree, master’s degree, post-master’s degree),
and certification (Oncology Nursing Society chemother-
apy certification, Oncology Certified Nurse, Advanced
Oncology Certified Nurse, other certification).
Baseline evaluation
After informed consent is obtained, participants will
complete a baseline questionnaire online at the secure
study website. Baseline blood draws will be performed on-
site at the conclusion of a participant’s scheduled work
shift. All plasma samples will be shipped to the University
of Michigan for processing and analyses for the detection
of 20 commonly-used chemotherapy drugs.
Spill reporting
If a spill occurs in the ambulatory oncology infusion
center throughout the 4-year study period, participants
will return to the secure study website and complete a
brief spill report. They will also have blood drawn at the
end of the shift to obtain drug levels. A second blood
draw will be performed 24 hours after the first one (or
the next available business day) to obtain estimated peak
and trough values, respectively.
Plasma analyses
Participants will provide blood for plasma sampling at the
baseline and post-intervention assessment, as well as with
the occurrence of any reported drug spill during the study.
The procedures below are used for all obtained samples. At
the end of a nurse’s shift, the nurse will report to the par-
ticipating site’s designated phlebotomy area. Trained and
credentialed phlebotomy staff will perform venipuncture
using standard technique and place whole blood into 5-mL
heparinized tubes. Cells will be removed from plasma by
centrifugation for 10 minutes at 1,000 to 2,000 × g using a
refrigerated centrifuge. Plasma will then be pipetted into a
clean polypropylene tube and stored in a −20°C or lower
freezer. After plasma samples are frozen, they will be
shipped by next-day air and on dry ice to the University of
Michigan.
To measure levels of potentially hazardous drugs from
the obtained samples, a specific and highly sensitive li-
quid chromatography-electrospray ionization-mass spec-
trometry (LC-ESI-MS) method will be established. We
will focus our efforts on the 20 drugs that are the most
commonly administered agents in ambulatory oncology
settings with chemical properties suitable for analysis.
However, as methods emerge for the measurement of
other drugs, we will consider these as nurses report ex-
posure outside of our original list of drugs. Signals from
the test drug will be monitored under the multiplereaction monitoring mode of the LC-ESI-MS for quan-
tification [33]. Ionization mode, precursor to product ion
transition, ion source parameters (potential, gas, tem-
perature, and so on), mobile phase, and column will be
optimized and selected under direct infusion and flow in-
jection analysis of the pure compound. The selection of
extraction method, including protein precipitation, liquid-
liquid extraction, and solid phase extraction, will depend
on the drug properties (for example, acidity content, lipo-
philicity, aqueous solubility and chemical stability). The
most efficient and specific extraction method will be used
for sample preparation.
Drugs with similar properties and similar measure-
ment methods (using the same column, same mobile
phase, and similar extraction conditions) will be grouped
into one method to simultaneously detect several drugs
in one injection. This technique will greatly enhance the
screening throughput. Each sample batch processed will
include plasma samples from healthy, unexposed volun-
teers to ensure calibration. The established method for
detecting multiple test drugs in one injection will be
evaluated for linearity, specificity, and sensitivity accord-
ing to guidance from the Food and Drug Administration
[34]. Results from the LC-ESI-MS analyses will be
entered into RedCAP, a secure, Health Insurance Porta-
bility and Accountability Act (HIPAA)-compliant cloud-
based data management platform [35]. Specimens and
survey data will be linked by unique study identifiers.
Statistical analysis
Survey data will be stored on the password-protected,
user-authenticated encrypted server behind a firewall.
Our hypotheses are focused on the efficacy of an audit
and feedback intervention to nurse participants. A total
of 382 nurses are expected to be sampled from 11 sites.
Each site is randomized into either control or interven-
tion condition. Because the nurses within the same site
are likely to show correlated outcomes, we will use lin-
ear mixed-effects models to account for the intraclass
correlation for the proposed cluster randomized trial
[36,37]. More specifically, we will use a random intercept
model in which a variable site is created to identify the
sites, and then adding site as a random effect to the
mixed model.
Aim 1 evaluates the efficacy of audit and feedback to
improve recommended PPE use (compared with an edu-
cational video). The outcome variable of the fixed-effect
structure is the PPE use scores. The predictor of the
fixed effect is the intervention indicator variable. The
data from the PPE use questionnaire and demographics
variables that are included in the fixed-effect structure
to increase the precision of estimates. The random effect
in the model is the site variable. We assume the site vari-
able follows a normal distribution with mean zero and is
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hypothesis is that there will be a significant intervention
effect such that nurses in sites receiving the treatment,
in addition to the web-based educational module, will
report higher PPE use scores compared to nurses in sites
randomized to receive only the control. Means within
time will be computed as descriptive statistics to help
describe the effect.
Aim 2 will determine whether knowledge about PPE
use and perceived risk of drug exposure mediate the ef-
fect of the treatment intervention on PPE use. The hy-
pothesis is that the effect of the treatment on PPE use
will be at least partially mediated by knowledge and per-
ceived risk. To measure the mediation effect, we fit two
linear mixed models. The first model is the same model
we use in Aim 1. The second model adds the two poten-
tial mediators in the first model. The mediator effect is
measured as the difference in the coefficients of the
intervention variable between the two models. A 95%
confidence interval is calculated for the estimate. If the
confidence interval does not cross zero, it shows that
mediation effect is statistically significant.
Aim 3 will determine whether the treatment interven-
tion effect on PPE use is moderated (strengthened or
weakened) by personal (experience, education, certifica-
tion) and organizational factors (workloads, practice en-
vironments, safety organizing). We will use mixed model
analyses that include receipt of the treatment interven-
tion, the moderator variables, and the products of treat-
ment intervention receipt with the moderator variables
as predictors of PPE use. Significance tests of the prod-
uct terms between moderator and intervention variables
will indicate whether moderation is present [38]. We
hypothesize that at least one of these moderator vari-
ables will interact significantly with the treatment inter-
vention. When the product term is significant, we will
conduct a post hoc analysis by plotting the PPE use ver-
sus intervention at various levels of the moderator vari-
ables. Using graphical presentations, we can show the
size of the intervention effect and how the effects vary
based on the values of moderate variables.
Sample size considerations and statistical power
The design and sample size for this study were deter-
mined in part by power analysis conducted by Optimal
Design software [39] that is designed specifically for
mixed models such as ours in which nurses are nested
within sites that are treated as a random factor. We con-
sidered power for detecting a medium sized effect of the
intervention and a medium sized multiple correlation
(both as defined by Cohen) [40]. We considered scenar-
ios with different numbers of clusters/sites, with dif-
ferent average numbers of nurses per site, and with
different levels of the intraclass correlation coefficient(ICC) ranging from 0.01 to 0.03. The ICC will be a meas-
ure of the extent that PPE use differs across sites. The
higher the ICC, the greater the sample size needed. ICCs
of up to 0.03 are common; therefore, we aimed to obtain
80% power for tests with a 2-tailed alpha of 0.05 to detect
medium sized effects with this ICC. Analysis revealed that
we will obtain this power if our sample includes 11 sites
with a mean of 26 participating nurses. In reality, our sites
have a mean of 35 nurses (range of 20 to 90), suggesting
that we will achieve 80% power even if we have a 25% de-
crease in the expected sample size (n = 287).Human subjects considerations
Potential participants will be invited to the study website
using their unique assigned study identifier and will also
complete informed consent. During the consent process,
they will have a yes/no option of providing additional
plasma and whole blood samples for our biorepository.
A data safety monitoring board comprised of three fac-
ulty members not involved in the project will review
study progress and human subjects concerns on a quar-
terly basis. Study withdrawals and potential adverse
events will also be reviewed at this meeting and reported
to our Institutional Review Board.Discussion
Despite three decades of data to suggest that nurses face
health risks from suboptimal use of personal protective
equipment when handling hazardous drugs, we have iden-
tified an alarming absence of tested interventions to im-
prove practice. This cluster, randomized controlled trial
will compare two interventions: an educational module
with an educational module plus feedback that will im-
prove nurses’ knowledge and reduce barriers to PPE use.Limitations
A key limitation to the project is the reliance on a self-
report measure of PPE use as the primary endpoint. Re-
source constraints and the frequent application of PPE
prohibit us from measuring PPE use through direct ob-
servation. However, the primary endpoint was validated
in the original study with direct observation. A second
limitation is our selection of elite cancer centers, as op-
posed to community-based oncology settings, will bias
our results toward conservative exposure rates. The par-
ticipating facilities are high-volume cancer centers that
currently provide training and PPE to their staff. For an
efficacy trial, larger samples of participants per cluster
are needed. It is our goal to move from efficacy to effect-
iveness in a larger, more diverse sample of oncology
practices that includes nurses and other health care
workers who are at risk for drug exposure.
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